Cumberland Pharmaceuticals (CPIX) earnings
In the quarter ended June 2026, Cumberland Pharmaceuticals had revenue of $166,458, down 98.5% on a year earlier, and diluted EPS of -0.29.
On August 4, 2026 it reported EPS of -0.20.
The next report is expected on Tuesday, November 3, 2026.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Tue Nov 3, 2026 | — | — | — |
| Last | Tue Aug 4, 2026 | — | — | -0.20 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Cumberland Pharmaceuticals's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $166,458 | -98.5% | -0.29 | — | -1898.7% | 2026-08-07 |
| Mar 31, 2026 | $9M | -22.0% | -0.22 | -375.0% | -34.3% | 2026-05-08 |
| Dec 31, 2025 | $14M | +31.1% | -0.09 | — | -10.0% | 2026-03-09 |
| Sep 30, 2025 | $8M | -8.7% | -0.13 | — | -23.7% | 2025-11-07 |
| Jun 30, 2025 | $11M | +10.0% | -0.05 | — | -28.8% | 2025-08-08 |
| Mar 31, 2025 | $12M | +37.8% | 0.08 | — | 11.0% | 2025-05-09 |
| Dec 31, 2024 | $10M | +11.6% | -0.14 | — | -17.7% | 2025-03-07 |
| Sep 30, 2024 | $9M | -9.9% | -0.11 | — | -18.6% | 2024-11-08 |
| Jun 30, 2024 | $10M | -9.6% | -0.08 | -233.3% | -10.4% | 2024-08-09 |
| Mar 31, 2024 | $8M | -7.9% | -0.14 | -1500.0% | -22.0% | 2024-05-10 |
| Dec 31, 2023 | $9M | +2.5% | -0.44 | — | -66.1% | 2024-03-13 |
| Sep 30, 2023 | $10M | -11.6% | -0.07 | — | -18.5% | 2023-11-13 |
Questions
When does Cumberland Pharmaceuticals report earnings?
Cumberland Pharmaceuticals's next earnings report is expected on November 3, 2026.
How did Cumberland Pharmaceuticals do last quarter?
In the quarter ended June 2026, Cumberland Pharmaceuticals had revenue of $166,458, down 98.5% on a year earlier, and diluted EPS of -0.29.
From Cumberland Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.